Sarcopenia in Acute Care Patients: Protocol for Sarcopenia 9+

NCT ID: NCT03917667

Last Updated: 2022-06-10

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-04-02
• Study Completion Date: 2022-06-01

Brief Summary

Sarcopenia is a disease characterized by progressive and generalized loss of skeletal muscle mass and strength, and is related to worse clinical outcomes, physical impairment, and mortality in all healthcare settings. This nutrition-related syndrome is a reversible condition, and can be effectively counteracted by exercise and nutritional support.

The prevalence of sarcopenia varies widely depending on the criteria, methods, and cut-off points used for its assessment. Although the European Working Group on Sarcopenia in Older People (EWGSOP) recommended assessing sarcopenia in geriatric patients in all care settings, few studies addressing hospitalized older patients have been carried out, mainly due to the characteristics of acute healthcare settings and their in-patients and because the criteria used are difficult to carry out there. Therefore, this condition remains under-recognized in the setting where this disease is likely to be more present.

Sarcopenia is expected to be a major healthcare problem in the upcoming years in Europe so, in response to this claim for Public Health Action, the European Union Geriatric Medicine Society founded the Special Interest Group (SIG) on sarcopenia that has taken the lead of bridging the gaps between clinical and research in sarcopenia field, in line with the Conference on Frailty and Sarcopenia Research Task Force, and the World Health Organization's strategies to promote Optimal Aging. This goal of SIG on sarcopenia by EuGMS is being carried out by promotion of collaboration among International scientific societies and institutions; they have recently launched the Revised European consensus on definition and diagnosis (EWGSOP2), the SARCUS project on ultrasound for sarcopenia assessment in European countries, and the first International Registry of patients with sarcopenia.

This study aims to provide an overview of sarcopenia assessment older patients hospitalized in acute-care geriatric units.

This is a longitudinal, prospective, observational study in consecutive hospitalized patients in the CHU Brugmann Hospital.

This study has 5 objectives :

1. To determine prevalence of sarcopenia among hospitalized patients in CHU Brugmann.

2. To determine incidence of sarcopenia during the hospital stay.

3. To identify risk factors for the development of sarcopenia at the time of admission and during hospitalization.

4. To assess sarcopenia as a risk factor for clinical adverse outcomes during hospitalization (hospital-acquired infections, falls, delirium, longer length-of-stay, disability, and mortality).

5. To assess sarcopenia as a risk factor for clinical adverse outcomes post-discharge (institutionalization, hospitalizations, falls, disability, and mortality) at 3- and 12-month follow-up.

Conditions

Sarcopenia

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Geriatric patients

Patients aged 70 years and older who are admitted to the acute care geriatric units.

EWGSOP2

Intervention Type: DIAGNOSTIC_TEST

EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.

Interventions

EWGSOP2

EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Patients aged 70 years and older who are admitted to the acute care geriatric units of the CHU Brugmann Hospital.

Exclusion Criteria

• Hip or lower limbs fractures, amputations,
• Terminally ill patients admitted for palliative care,
• Neurological patients with hemiplegia or stroke limiting the walking evaluation

• Minimum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Murielle Surquin

OTHER

Sponsor Role: lead

Responsible Party

Murielle Surquin

Head of Geriatry Department

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Murielle Surquin, MD

Role: PRINCIPAL_INVESTIGATOR

CHU Brugmann

Locations

CHU Brugmann

Brussels, , Belgium

UZ Gent

Ghent, , Belgium

Countries

Belgium

Other Identifiers

CHUB-Sarcopenia 9+

Identifier Type: -

Identifier Source: org_study_id